Researchers sought to compare the effectiveness and cost-savings of the recombinant subunit zoster vaccine with that of the live attenuated zoster vaccine in individuals aged ≥50 years.
Only 29% of 2016 survey respondents reported that they strongly agreed that the burden of herpes zoster in patients aged 50 to 59 years old is sufficient to make a vaccine important.
Investigators found a decline in pediatric herpes zoster incidence and a significantly lower incidence among vaccinated children.
A 2-dose course of recombinant zoster vaccine decreased the incidence of herpes zoster in adults who had undergone recent autologous hematopoietic stem cell transplantation.
From 2003 to 2014, there was a decrease in herpes zoster incidence among children, with lower incidence rates for varicella-vaccinated versus unvaccinated children.
From 2004 to 2012, there was a more than threefold increase in the incidence of herpes zoster ophthalmicus in the US.
Compared with the live zoster vaccine, adjuvanted recombinant zoster vaccine had significantly higher vaccine efficacy (VE) against herpes zoster (HZ) and postherpetic neuralgia in older adults. There were also no differences in safety between the 2 vaccines, according to a network meta-analysis of randomized controlled trials published in Vaccine. This systematic review of published randomized…
Investigators assessed the risk for herpes zoster and provided recommendations regarding treatment in patients with psoriasis.
A 34-year-old man with a history of ankylosing spondylitis presented to the hospital complaining of fever, cough, malaise, and widespread vesicular rash.
The 2007 and 2008 shingles and varicella vaccination recommendations may have contributed to the declining herpes zoster hospitalization rates in some groups.
